Literature DB >> 17892515

Regression of intestinal adenomas by vaccination with heat shock protein 105-pulsed bone marrow-derived dendritic cells in Apc(Min/+) mice.

Kazunori Yokomine1, Tetsuya Nakatsura, Satoru Senju, Naomi Nakagata, Motozumi Minohara, Jun-Ichi Kira, Yutaka Motomura, Tatsuko Kubo, Yutaka Sasaki, Yasuharu Nishimura.   

Abstract

Heat shock protein (HSP) 105 is overexpressed in various cancers, but is expressed at low levels in many normal tissues, except for the testis. A vaccination with HSP105-pulsed bone marrow-derived dendritic cells (BM-DC) induced antitumor immunity without causing an autoimmune reaction in a mouse model. Because Apc(Min/+) mice develop multiple adenomas throughout the intestinal tract by 4 months of age, the mice provide a clinically relevant model of human intestinal tumor. In the present study, we investigated the efficacy of the HSP105-pulsed BM-DC vaccine on tumor regression in the Apc(Min/+) mouse. Western blot and immunohistochemical analyses revealed that the tumors of the Apc(Min/+) mice endogenously overexpressed HSP105. Immunization of the Apc(Min/+) mice with a HSP105-pulsed BM-DC vaccine at 6, 8, and 10 weeks of age significantly reduced the number of small-intestinal polyps accompanied by infiltration of both CD4(+) and CD8(+) T cells in the tumors. Cell depletion experiments proved that both CD4(+) and CD8(+) T cells play a critical role in the activation of antitumor immunity induced by these vaccinations. These findings indicate that the HSP105-pulsed BM-DC vaccine can provide potent immunotherapy for tumors that appear spontaneously as a result of the inactivation of a tumor suppressor gene, such as in the Apc(Min/+) mouse model.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17892515     DOI: 10.1111/j.1349-7006.2007.00612.x

Source DB:  PubMed          Journal:  Cancer Sci        ISSN: 1347-9032            Impact factor:   6.716


  5 in total

Review 1.  Immunotherapy in preneoplastic disease: targeting early procarcinogenic inflammatory changes that lead to immune suppression and tumor tolerance.

Authors:  Bridget Keenan; Elizabeth M Jaffee
Journal:  Ann N Y Acad Sci       Date:  2013-05       Impact factor: 5.691

Review 2.  Targeting Heat Shock Proteins in Cancer: A Promising Therapeutic Approach.

Authors:  Suman Chatterjee; Timothy F Burns
Journal:  Int J Mol Sci       Date:  2017-09-15       Impact factor: 5.923

3.  Molecular Pathway Analysis Indicates a Distinct Metabolic Phenotype in Women With Right-Sided Colon Cancer.

Authors:  Yazhi Sun; Varvara Mironova; Ying Chen; Elliott P F Lundh; Qian Zhang; Yuping Cai; Vasilis Vasiliou; Yawei Zhang; Rolando Garcia-Milian; Sajid A Khan; Caroline H Johnson
Journal:  Transl Oncol       Date:  2019-11-21       Impact factor: 4.243

4.  Expression of Heat Shock Protein 105 in Cutaneous Squamous Cell Carcinoma: Correlation with Clinicopathological Characteristics.

Authors:  Meng Jia; Feng-Zeng Li; Qian Ye; Ke-Jun Chen; Sheng Fang
Journal:  Clin Cosmet Investig Dermatol       Date:  2021-06-14

5.  Identification of HLA-A2 or HLA-A24-restricted CTL epitopes for potential HSP105-targeted immunotherapy in colorectal cancer.

Authors:  Yu Sawada; Hiroyuki Komori; Yoshiyuki Tsunoda; Manami Shimomura; Mari Takahashi; Hideo Baba; Masaaki Ito; Norio Saito; Hiroyuki Kuwano; Itaru Endo; Yasuharu Nishimura; Tetsuya Nakatsura
Journal:  Oncol Rep       Date:  2013-12-20       Impact factor: 3.906

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.